World Health Organization to Review Merck’s Investigational Ebola Vaccine for Emergency Use Assessment and Listing
Dateline City:
KENILWORTH, N.J.
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
announced today that the application for Emergency Use Assessment and
Listing (EUAL) for the company’s investigational Ebola Zaire vaccine,
V920 (rVSV∆G-ZEBOV-GP, live attenuated), has been accepted for review by
the World Health Organization (WHO).
Language:
English
Contact:
MerckMedia:Pamela Eisele, 267-305-3558Skip Irvine, 215-652-6059orInvestors:Teri Loxam, 908-740-1986Justin Holko, 908-423-5088
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more
Source: Merck.com - Corporate News - Category: Pharmaceuticals Tags: Vaccine News Corporate News Latest News #Merck #MRK Ebola MSD NYSE:MRK Source Type: news
More News: Ebola | Ebola Vaccine | Emergency Medicine | Health | International Medicine & Public Health | Merck | Pharmaceuticals | Vaccines | WHO